ArticleScience translational medicine2015
Drug testing in the patient: toward personalized cancer treatment.
Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung adenocarcinoma.Briefings in bioinformatics · 2025Article
- Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024Review
- Engineering and physical sciences in oncology: challenges and opportunities.Nature reviews. Cancer · 2017Review
- Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.Convergent science physical oncology · 2017Article
- Real-time detection of carboplatin using a microfluidic system.The Analyst · 2016Article
- Cytotoxic and targeted therapy for hereditary cancers.Hereditary cancer in clinical practice · 2016Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two different devices show that delivery of cancer drugs directly into tumors in vivo can indicate cancer sensitivity; if implemented in clinical practice, these devices have the potential to reduce indiscriminate drug use, to improve survival, and to reduce unnecessary adverse effects (Jonas et al. and Klinghoffer et al., this issue).
Indexed as
Identifiers
25904739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.